keyword
MENU ▼
Read by QxMD icon Read
search

squamous cell lung cancer

keyword
https://www.readbyqxmd.com/read/28748556/systemic-therapy-treatment-patterns-in-patients-with-advanced-non-small-cell-lung-cancer-nsclc-pivotal-study
#1
J de Castro, P Tagliaferri, V C C de Lima, S Ng, M Thomas, A Arunachalam, X Cao, S Kothari, T Burke, H Myeong, A Grattan, D H Lee
The aim of this multinational retrospective cohort study, conducted at academic and community oncology centres, was to describe real-world treatment patterns for patients with a confirmed diagnosis of advanced/metastatic (stage IIIB/IV) non-small cell lung cancer (NSCLC) who initiated first-line systemic therapy from January 2011 through June 2014. The study included 1265 patients in Italy, Spain, Germany, Australia, Korea, Taiwan and Brazil. The proportion of patients with squamous versus non-squamous NSCLC was approximately 20% versus 75%, and associated patient demographic characteristics were similar in all countries, excepting race...
July 27, 2017: European Journal of Cancer Care
https://www.readbyqxmd.com/read/28748555/digitalis-use-and-lung-cancer-risk-by-histological-type-in-men
#2
Wentao Li, Shao-Hua Xie, Lap-Ah Tse, Jesper Lagergren
Lung cancer risk and tumor characteristics differ between sexes. Estrogen has been suggested to counteract lung cancer development. We aimed to test the hypothesis that digitalis use decreases lung cancer risk due to its estrogenic and other anticancer properties in men. This was a nationwide Swedish population-based cohort study between July 1, 2005 and December 31, 2013. Data on the use of digitalis and organic nitrates in all male individuals were derived from the Swedish Prescribed Drug Registry. New lung cancer diagnoses among cohort participants were identified from the Swedish Cancer Registry...
July 27, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28745824/gemcitabine-combined-with-cisplatin-as-adjuvant-chemotherapy-for-non-small-cell-lung-cancer-a-retrospective-analysis
#3
Di Ma, Jing Wang, Xuezhi Hao, Yan Wang, Xingsheng Hu, Puyuan Xing, Junling Li
BACKGROUND: This study was conducted to evaluate the value of gemcitabine combined with cisplatin as adjuvant chemotherapy for radical resection of non-small cell lung cancer. METHODS: Data of 100 patients who had undergone radical resection of non-small cell lung cancer and were treated with cisplatin/gemcitabine as adjuvant chemotherapy between June 2007 and December 2010 at the Chinese Academy of Medical Sciences were reviewed. RESULTS: The median age was 59 years (range 36-73); 82% of the patients were male...
July 26, 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/28742456/dietary-fat-intake-and-lung-cancer-risk-a-pooled-analysis
#4
Jae Jeong Yang, Danxia Yu, Yumie Takata, Stephanie A Smith-Warner, William Blot, Emily White, Kim Robien, Yikyung Park, Yong-Bing Xiang, Rashmi Sinha, DeAnn Lazovich, Meir Stampfer, Rosario Tumino, Dagfinn Aune, Kim Overvad, Linda Liao, Xuehong Zhang, Yu-Tang Gao, Mattias Johansson, Walter Willett, Wei Zheng, Xiao-Ou Shu
Purpose Dietary fat may play a role in lung carcinogenesis. Findings from epidemiologic studies, however, remain inconsistent. In this pooled analysis of 10 prospective cohort studies from the United States, Europe, and Asia, we evaluated the associations of total and specific types of dietary fat with lung cancer risk. Methods Cox regression was used to estimate hazard ratios (HRs) and 95% CIs in each cohort. Study-specific risk estimates were pooled by random- or fixed-effects meta-analysis. The first 2 years of follow-up were excluded to address potential influence of preclinical dietary changes...
July 25, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28741444/mild-pulmonary-emphysema-a-risk-factor-for-interstitial-lung-disease-when-using-cetuximab-for-squamous-cell-carcinoma-of-the-head-and-neck
#5
Isaku Okamoto, Kiyoaki Tsukahara, Hiroki Sato, Ray Motohashi, Daisuke Yunaiyama, Akira Shimizu
BACKGROUND: Interstitial lung disease (ILD) is an occasionally fatal adverse event associated with cetuximab (Cmab) therapy. Our objective was to clarify to what degree pulmonary emphysema is a risk factor in the treatment of head and neck cancer with Cmab through a retrospective analysis. METHODS: Subjects were 116 patients who were administered Cmab for head and neck squamous cell carcinoma. The degree of pulmonary emphysema before initiating treatment with Cmab was visually assessed retrospectively, with scoring according to the Goddard classification used in Japanese chronic obstructive pulmonary disease (COPD) guidelines for chest computed tomography (CT)...
July 25, 2017: Acta Oto-laryngologica
https://www.readbyqxmd.com/read/28741198/significance-of-body-mass-index-for-postoperative-outcomes-after-lung-cancer-surgery-in-elderly-patients
#6
Katsunari Matsuoka, Tetsu Yamada, Takahisa Matsuoka, Shinjiro Nagai, Mitsuhiro Ueda, Yoshihiro Miyamoto
BACKGROUND: Although the frequency of elderly patients undergoing surgery for lung cancer has been increasing, indications for surgery in elderly patients are still controversial. Low body mass index is a significant predictor of poor prognosis in elderly patients with various medical conditions. Then, we examined the long-term outcome of elderly patients who had undergone thoracic surgery for lung cancer, focusing especially on body mass index. PATIENTS AND METHODS: Between January 2004 and March 2011, 1673 patients with lung cancer underwent surgical resection at our institution...
July 24, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/28740665/decrease-in-performance-status-after-lobectomy-mean-poor-prognosis-in-elderly-lung-cancer-patients
#7
Yo Kawaguchi, Jun Hanaoka, Yasuhiko Oshio, Masayuki Hashimoto, Tomoyuki Igarashi, Yoko Kataoka, Ryosuke Kaku, Yuki Namura, Akira Akazawa
BACKGROUND: Surgery remains the best treatment for obtaining cure in patients with resectable lung cancer, regardless of age. In elderly patients, however, the presumed fear of decreased performance status (PS) after lobectomy has resulted in the delivery of sub-optimal cancer surgery. Surgical decision making for such patients would become easier if post-lobectomy survival benefits and changes in PS were well defined. METHODS: We reviewed patients aged 75 years or older who received lobectomy for non-small cell lung cancer (NSCLC) at our hospital between January 2004 and December 2014...
June 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28740574/phase-i-ii-study-of-erlotinib-carboplatin-pemetrexed-and-bevacizumab-in-chemotherapy-na%C3%A3-ve-patients-with-advanced-non-squamous-non-small-cell-lung-cancer-harboring-epidermal-growth-factor-receptor-mutation
#8
Takayasu Kurata, Aya Nakaya, Takashi Yokoi, Maiko Niki, Kayoko Kibata, Yuki Takeyasu, Yoshitaro Torii, Yuichi Katashiba, Makoto Ogata, Takayuki Miyara, Shosaku Nomura
BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors significantly prolong the progression-free survival of patients with non-squamous non-small cell lung cancer (NSCLC). However, most patients develop tumor regrowth and their prognosis remains poor. A new treatment strategy for NSCLC harboring EGFR mutation is therefore necessary. METHODS: In phase I, eligible patients were administered oral erlotinib daily and intravenous pemetrexed, carboplatin, and bevacizumab every 3 weeks for four cycles with maintenance of pemetrexed and bevacizumab until progressive disease was observed...
May 2017: Genes & Cancer
https://www.readbyqxmd.com/read/28740455/insulin-like-growth-factor-1-receptor-expression-in-advanced-non-small-cell-lung-cancer-and-its-impact-on-overall-survival
#9
Mojca Humar, Izidor Kern, Gregor Vlacic, Vedran Hadzic, Tanja Cufer
BACKGROUND: The insulin-like growth factor 1 receptor (IGF1R) expression has been addressed as a potential prognostic marker in non-small-cell lung cancer (NSCLC) in various studies; however, the associations between IGF1R expression and prognosis of advanced NSCLC patients is still controversial. The aim of our observational, cohort study was to evaluate the expression of IGF1R in advanced NSCLC and its prognostic role. A subgroup analysis was performed to address the influence of pre-existing type 2 diabetes mellitus (T2DM) status on IGF1R expression and overall survival (OS)...
June 2017: Radiology and Oncology
https://www.readbyqxmd.com/read/28739772/efficacy-and-safety-of-nab-paclitaxel-as-second-line-chemotherapy-for-locally-advanced-and-metastatic-non-small-cell-lung-cancer
#10
Wenjing Wong, Ping Sun, Zhengbin Mu, Jiannan Liu, Caiyan Yu, Aina Liu
AIM: To investigate the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) for locally advanced or metastatic non-small cell lung cancer (NSCLC) as second-line chemotherapy. PATIENTS AND METHODS: We retrospectively reviewed the treatment of 34 patients with advanced NSCLC whose first-line treatment had failed. These patients received nab-paclitaxel 260 mg/m(2) on day 1 and day 8 of a 21-day cycle from July 2014 to February 2016. One cycle of treatment lasted 3 weeks and all patients completed more than two cycles...
August 2017: Anticancer Research
https://www.readbyqxmd.com/read/28739316/validation-of-the-disease-specific-gpa-for-patients-with-1-to-3-synchronous-brain-metastases-in-newly-diagnosed-nsclc
#11
Neil M Woody, Matthew D Greer, Chandana A Reddy, Gregory M M Videtic, Samuel T Chao, Erin S Murphy, John H Suh, Liliana Angelov, Gene H Barnett, Michael A Vogelbaum, Kevin L Stephans
BACKGROUND: The disease-specific graded prognostic assessment (DS-GPA) for brain metastases is a powerful prognostic tool but has not been validated for patients with synchronous brain metastases (SBM) in newly diagnosed non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: We identified patients with newly diagnosed NSCLC with 1 to 3 SBM treated with stereotactic radiosurgery (SRS) between 1997 and 2012. We included patients whose brain metastases were treated with SRS alone or combined SRS and whole-brain radiotherapy (WBRT)...
July 6, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28738964/-clinical-research-on-albumin-bound-paclitaxel-based-therapy-in-advanced-lung-cancer
#12
Xu Li, Bin Ai, Ping Zhang, Lin Li, Xiaonan Wu
BACKGROUND: Albumin-bound paclitaxel is a novel paclitaxel formulation formed by the combination of paclitaxel and human serum albumin (HSA) to improve the efficacy of paclitaxel and reduce its adverse reactions. The aim of this retrospective study is to observe the efficacy and safety of albumin-bound paclitaxel-based therapy in the treatment of lung cancer. METHODS: We have enrolled 50 patients with advanced or unresectable retreatment lung cancer who were admitted from November 2011 to December 2014...
July 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28736363/-clinical-characteristics-and-risk-factors-affecting-outcomes-of-elderly-patients-with-non-small-cell-lung-cancer-complicated-by-chronic-obstructive-pulmonary-disease
#13
Peng Wang, Dong Zhang, Xue-Guang Guo, Bao-Jun Sun, Xiang-Qun Fang, Ge-Ping Qu, Chang-Ting Liu
OBJECTIVE: To investigate the clinical features, treatment strategy and risk factors affecting the prognosis of elderly patients with non-small cell lung cancer (NSCLC) complicated by chronic obstructive pulmonary disease (COPD). METHODS: We retrospectively analyzed the data of elderly patietns (>60 years) with newly diagnosed NSCLC complicated by COPD at the Geriatric Institution of General Hospital of PLA between January, 2000 and June, 2015. The clinical data collected included history of smoking, pulmonary function test results, initial treatments, TNM stage, chief complaints, comorbidities and laboratory tests...
July 20, 2017: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://www.readbyqxmd.com/read/28734892/correlation-between-rna-seq-and-microarrays-results-using-tcga-data
#14
Li Chen, Fenghao Sun, Xiaodong Yang, Yulin Jin, Mengkun Shi, Lin Wang, Yu Shi, Cheng Zhan, Qun Wang
RNA sequencing (RNA-Seq) and microarray are two of the most commonly used high-throughput technologies for transcriptome profiling; however, they both have their own inherent strengths and limitations. This research aims to analyze the correlation between microarrays and RNA-Seq detection of transcripts in the same tissue sample to explore the reproducibility between the techniques. Using data of RNA-Seq v2 and three different microarrays provided by The Cancer Genome Atlas, 11,120 genes of 111 lung squamous cell carcinoma samples were simultaneously detected by the four methods...
July 19, 2017: Gene
https://www.readbyqxmd.com/read/28732824/a-clinicopathological-study-of-surgically-resected-lung-cancer-in-patients-with-usual-interstitial-pneumonia
#15
Yasutaka Watanabe, Yoshinori Kawabata, Nobuyuki Koyama, Tomohiko Ikeya, Eishin Hoshi, Noboru Takayanagi, Shinichiro Koyama
BACKGROUND: The clinicopathological characteristics of lung cancer with concomitant usual interstitial pneumonia (UIP) are insufficiently understood. This study aimed to elucidate a characteristic pathological feature of lung cancer that develops in patients with UIP, with a focus on the location of its onset. METHODS: We reviewed surgically obtained specimens, including 547 tumors from 526 patients who underwent lobectomy for lung cancer. Surveyed patients were classified into three groups: patients with UIP (UIP group), patients with lung pathology other than UIP (non-UIP group), and patients without any associated lung pathology (normal group)...
August 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/28732044/the-prognostic-impact-of-human-papillomavirus-status-following-treatment-failure-in-oropharyngeal-cancer
#16
Eesha Dave, Umut Ozbek, Vishal Gupta, Eric Genden, Brett Miles, Marita Teng, Marshall Posner, Krzysztof Misiukiewicz, Richard L Bakst
INTRODUCTION: Despite the human papillomavirus conferring a better prognosis in the primary treatment setting, the prognostic impact of viral status after treatment failure in oropharyngeal squamous cell carcinoma patients is poorly understood. METHODS: We retrospectively identified 33 oropharyngeal squamous cell carcinoma (OPC) patients with local and/or distant disease recurrence post-treatment, and looked at metastatic patterns, time to failure and survival patterns by HPV status...
2017: PloS One
https://www.readbyqxmd.com/read/28732018/carboplatin-with-intravenous-and-subsequent-oral-administration-of-vinorelbine-in-resected-non-small-cell-lung-cancer-in-real-world-set-up
#17
Vítězslav Kolek, Ivona Grygárková, Leona Koubková, Jana Skřičková, Jiřina Švecová, Dimka Sixtová, Jiří Bartoš, Aleš Tichopád
OBJECTIVES: Adjuvant cisplatin-based chemotherapy is recommended for routine use in patients with Stage IIA, IIB or IIIA non-small cell lung cancer (NSCLC) after complete resection. Results obtained for Stage IB were not conclusive. While vinorelbine plus cisplatin is the preferred choice after resection, combining vinorelbine with carboplatin promises improved compliance and delivery of drugs due to lower toxicity. We evaluated the impact of this option on treatment compliance and survival under real-world conditions...
2017: PloS One
https://www.readbyqxmd.com/read/28731174/lhx3-is-an-early-stage-and-radiosensitivity-prognostic-biomarker-in-lung-adenocarcinoma
#18
Xin Lin, Yan Li, Jin Wang, Fei Han, Shuang Lu, Yu Wang, Wenjian Luo, Mingqian Zhang
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. We previously identified LHX3 as a new preferentially expressed gene in NSCLC. In the present study, we sought to determine its expression, the clinical relevance and the functional roles in NSCLC. LHX3 expression is sharply increased in carcinoma tissues compared to non-carcinoma tissues. Relational analysis reveals a significant association between LHX3 expression and clinical stage (n=172, p=0.032) or radiotherapy (n=167, p=0.022) of patients...
July 18, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28730709/the-role-of-the-cytopathologist-in-subtyping-and-epidermal-growth-factor-receptor-testing-in-non-small-cell-lung-cancer-an-institutional-experience
#19
A Sekar, N Gupta, A Rajwanshi, R Chaturvedi, N Singh, A Lal
OBJECTIVE: Approximately 10% of non-small-cell lung cancer (NSCLC) remains unclassifiable as NSCLC-not otherwise specified (NOS), after using a panel of immunomarkers. The present study was undertaken to assess sensitivity and specificity of immunomarkers in sub-typing NSCLC on fine needle aspiration cytology (FNAC). Epidermal growth factor receptor (EGFR) mutations were also detected in these samples. METHODS: Sixty cases of NSCLC including 15 squamous cell carcinoma (SCC), 15 adenocarcinomas (ADC) and 30 NSCLC-NOS reported on FNAC were included in the study...
July 21, 2017: Cytopathology: Official Journal of the British Society for Clinical Cytology
https://www.readbyqxmd.com/read/28729180/symptom-and-quality-of-life-improvement-in-lux-lung-8-an-open-label-phase-iii-study-of-second-line-afatinib-versus-erlotinib-in-patients-with-advanced-squamous-cell-carcinoma-of-the-lung-after-first-line-platinum-based-chemotherapy
#20
Enriqueta Felip, Vera Hirsh, Sanjay Popat, Manuel Cobo, Andrea Fülöp, Charles Dayen, José M Trigo, Richard Gregg, Cornelius F Waller, Jean-Charles Soria, Glenwood D Goss, James Gordon, Bushi Wang, Michael Palmer, Eva Ehrnrooth, Shirish M Gadgeel
INTRODUCTION: In the phase III LUX-Lung 8 trial, afatinib significantly improved progression-free survival (PFS) and overall survival (OS) versus erlotinib in patients with squamous cell carcinoma (SCC) of the lung progressing during or after platinum-based chemotherapy. Patient-reported outcomes (PROs) and health-related quality of life (QoL) in these patients are presented. PATIENTS AND METHODS: Patients (n = 795) were randomized 1:1 to oral afatinib (40 mg/d) or erlotinib (150 mg/d)...
June 23, 2017: Clinical Lung Cancer
keyword
keyword
77522
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"